

Kari G Rabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5895397/publications.pdf>

Version: 2024-02-01

146
papers

6,562
citations

66234

42
h-index

69108

77
g-index

147
all docs

147
docs citations

147
times ranked

10206
citing authors

#	ARTICLE	IF	CITATIONS
1	Detectable clonal mosaicism and its relationship to aging and cancer. <i>Nature Genetics</i> , 2012, 44, 651-658.	9.4	519
2	Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2401.	3.8	375
3	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 166-175.	7.7	282
4	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 49-62.	0.6	244
5	Probability of Pancreatic Cancer Following Diabetes: A Population-Based Study. <i>Gastroenterology</i> , 2005, 129, 504-511.	0.6	234
6	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. <i>Genetics in Medicine</i> , 2015, 17, 569-577.	1.1	231
7	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015, 47, 911-916.	9.4	224
8	Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	193
9	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	5.8	188
10	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013, 162, 774-782.	1.2	187
11	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	9.4	179
12	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. <i>Nature Genetics</i> , 2010, 42, 661-664.	9.4	152
13	Pancreatic Cancer Genetic Epidemiology Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 704-710.	1.1	133
14	Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 3959-3963.	0.8	123
15	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011, 117, 1911-1916.	0.6	118
16	Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. <i>European Journal of Human Genetics</i> , 2011, 19, 472-478.	1.4	112
17	Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. <i>Genetics in Medicine</i> , 2018, 20, 119-127.	1.1	109
18	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 4777-4787.	2.0	107

#	ARTICLE	IF	CITATIONS
19	Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. <i>Carcinogenesis</i> , 2012, 33, 1384-1390.	1.3	102
20	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017, 58, 1630-1639.	0.6	102
21	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. <i>American Journal of Human Genetics</i> , 2015, 96, 487-497.	2.6	101
22	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
23	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. <i>Nature Communications</i> , 2016, 7, 11843.	5.8	86
24	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
25	Cystic fibrosis transmembrane conductance regulator (<i>CFTR</i>) gene mutations and risk for pancreatic adenocarcinoma. <i>Cancer</i> , 2010, 116, 203-209.	2.0	80
26	Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. <i>Cancer</i> , 2005, 104, 388-394.	2.0	78
27	Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. <i>Cancer Causes and Control</i> , 2015, 26, 1583-1591.	0.8	78
28	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015, 121, 2883-2891.	2.0	77
29	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. <i>Haematologica</i> , 2015, 100, 1180-1188.	1.7	70
30	Transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to <i>de novo</i> Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 334-338.	2.0	69
31	Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. <i>Journal of Clinical Oncology</i> , 2016, 34, 1898-1904.	0.8	69
32	New-onset diabetes in pancreatic cancer: A study in the primary care setting. <i>Pancreatology</i> , 2012, 12, 156-161.	0.5	68
33	Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. <i>British Journal of Haematology</i> , 2017, 178, 394-402.	1.2	66
34	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	4.2	65
35	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020, 105, 765-773.	1.7	64
36	Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. <i>Haematologica</i> , 2014, 99, 140-147.	1.7	60

#	ARTICLE	IF	CITATIONS
37	Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 458-465.	1.7	60
38	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <i>American Journal of Hematology</i> , 2016, 91, 1090-1095.	2.0	58
39	Identification of recurrent truncated <i>DDX3X</i> mutations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 169, 445-448.	1.2	54
40	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. <i>Blood</i> , 2016, 128, 2093-2095.	0.6	52
41	Pancreatic cancer: associations of inflammatory potential of diet, cigarette smoking and long-standing diabetes. <i>Carcinogenesis</i> , 2016, 37, 481-490.	1.3	50
42	Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1238-1245.	1.1	48
43	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. <i>EBioMedicine</i> , 2015, 2, 572-582.	2.7	43
44	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2712-2719.	0.6	42
45	Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the <i>ATM</i> Gene. <i>JAMA Oncology</i> , 2021, 7, 1664.	3.4	39
46	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018, 183, 421-427.	1.2	37
47	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020, 9, 3390-3399.	1.3	36
48	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. <i>Cancer</i> , 2014, 120, 2000-2005.	2.0	33
49	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017, 58, 1376-1383.	0.6	33
50	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021, 100, 143-155.	0.8	32
51	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1185-1191.	1.1	29
52	Impact of Diabetes Mellitus on Clinical Outcomes in Patients Undergoing Surgical Resection for Pancreatic Cancer: A Retrospective, Cohort Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 1484-1492.	0.2	26
53	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 688-698.	0.6	26
54	Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6505-6512.	3.2	24

#	ARTICLE	IF	CITATIONS
55	<sc>CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2017, 178, 99-105.	1.2	23
56	Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. Carcinogenesis, 2018, 39, 1056-1067.	1.3	23
57	<i>CDKN2A</i> Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1364-1370.	1.1	23
58	Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer. Tumor Biology, 2015, 36, 7431-7437.	0.8	22
59	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood, 2018, 131, 2541-2551.	0.6	21
60	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	3.3	21
61	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	3.0	21
62	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). Leukemia, 2021, 35, 239-244.	3.3	21
63	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. American Journal of Hematology, 2016, 91, 687-691.	2.0	20
64	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood, 2021, 138, 149-159.	0.6	20
65	<i>IGH</i> translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. American Journal of Hematology, 2019, 94, 338-345.	2.0	19
66	Comparison between the CLLâ€PI and the <sc>B</sc>arcelonaâ€<sc>B</sc>no prognostic model: Analysis of 1299 newly diagnosed cases. American Journal of Hematology, 2018, 93, E35-E37.	2.0	18
67	Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history. Hereditary Cancer in Clinical Practice, 2012, 10, 8.	0.6	17
68	Should Researchers Offer Results to Family Members of Cancer Biobank Participants? A Mixed-Methods Study of Proband and Family Preferences. AJOB Empirical Bioethics, 2019, 10, 1-22.	0.8	17
69	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. American Journal of Hematology, 2020, 95, 906-917.	2.0	17
70	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica, 2020, 105, 2675-2678.	1.7	17
71	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood, 2021, 137, 2046-2056.	0.6	16
72	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica, 2018, 103, e237-e240.	1.7	15

#	ARTICLE	IF	CITATIONS
73	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	2.0	15
74	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980.	1.9	15
75	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	1.7	15
76	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388.	0.6	15
77	Variants Associated with Susceptibility to Pancreatic Cancer and Melanoma Do Not Reciprocally Affect Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1121-1124.	1.1	14
78	Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 130-136.	0.6	14
79	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 677-680.	2.0	14
80	Do Variants Associated with Susceptibility to Pancreatic Cancer and Type 2 Diabetes Reciprocally Affect Risk?. <i>PLoS ONE</i> , 2015, 10, e0117230.	1.1	14
81	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017, 92, 1362-1369.	2.0	13
82	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2022, 97, 90-98.	2.0	13
83	Receptivity and preferences of pancreatic cancer family members for participating in lifestyle programs to reduce cancer risk. <i>Hereditary Cancer in Clinical Practice</i> , 2013, 11, 3.	0.6	11
84	Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 971-974.	1.1	11
85	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e22-e25.	1.7	11
86	Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Proband's Susceptibility Gene Mutation Status. <i>Journal of the National Cancer Institute</i> , 2019, 111, 264-271.	3.0	10
87	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	3.3	10
88	Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. <i>Oncotarget</i> , 2018, 9, 37173-37184.	0.8	9
89	Association of elevated serum free light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 59.	2.8	9
90	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020, 95, E57-E60.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. Blood Cancer Journal, 2022, 12, 18.	2.8	9
92	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	3.3	8
93	Predictive value of the <sc>CLL</sc>â€<sc>IPI</sc> in <sc>CLL</sc> patients receiving chemo-immunotherapy as first-line treatment. European Journal of Haematology, 2018, 101, 703-706.	1.1	8
94	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Research, 2021, 81, 3134-3143.	0.4	8
95	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. Blood, 2015, 126, 717-717.	0.6	8
96	Psychological Impact of Learning & CDKN2A Variant Status as a Genetic Research Result. Public Health Genomics, 2018, 21, 154-163.	0.6	7
97	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer Journal, 2021, 11, 47.	2.8	7
98	Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result. Genetics in Medicine, 2019, 21, 2468-2477.	1.1	6
99	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2735-2739.	1.1	6
100	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer Journal, 2021, 11, 140.	2.8	6
101	Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1784-1791.	1.1	5
102	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Research, 2020, 80, 4004-4013.	0.4	5
103	Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1492-1500.	1.1	5
104	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. Blood, 2013, 122, 1642-1642.	0.6	5
105	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2950-2950.	0.6	5
106	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2020, 83, 1581-1589.	0.6	4
107	Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia. Blood, 2013, 122, 2867-2867.	0.6	4
108	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. Blood, 2013, 122, 4179-4179.	0.6	4

#	ARTICLE	IF	CITATIONS
109	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. <i>British Journal of Cancer</i> , 2021, 125, 1712-1717.	2.9	4
110	Pancreatic cancer risk to siblings of probands in bilineal cancer settings. <i>Genetics in Medicine</i> , 2022, 24, 1008-1016.	1.1	4
111	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019, 134, 3050-3050.	0.6	3
112	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. <i>Blood</i> , 2017, 130, 831-831.	0.6	3
113	Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 372-381.	1.1	3
114	A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. <i>Journal of Biological Chemistry</i> , 2021, 296, 100634.	1.6	2
115	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. <i>Blood</i> , 2013, 122, 4178-4178.	0.6	2
116	Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7525-7525.	0.8	2
117	Shorter Treatment-Na ⁺ Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 210-216.	1.1	2
118	The prognostic significance of $\langle \text{sc} \rangle \text{del}6\text{q}23 \langle / \text{sc} \rangle$ in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E203-E206.	2.0	1
119	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020, 136, 39-40.	0.6	1
120	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 4152-4152.	0.6	1
121	Accuracy of Smoking Status Reporting. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 801-809.	1.2	1
122	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
123	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. <i>Leukemia</i> , 2022, , .	3.3	1
124	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40.	0.2	1
125	Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. <i>Journal of Hematopathology</i> , 2020, 13, 221-229.	0.2	0
126	Bayesian copy number detection and association in large-scale studies. <i>BMC Cancer</i> , 2020, 20, 856.	1.1	0

#	ARTICLE	IF	CITATIONS
127	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients., Blood, 2011, 118, 3903-3903.	0.6	0
128	Prevalence of MBL Increases Over Time In Relatives of CLL Families., Blood, 2011, 118, 3881-3881.	0.6	0
129	In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics. Blood, 2011, 118, 2835-2835.	0.6	0
130	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. Blood, 2011, 118, 4610-4610.	0.6	0
131	Clonal Evolution In Patients With Previously Untreated Chronic Lymphocytic Leukemia. Blood, 2013, 122, 1643-1643.	0.6	0
132	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. Blood, 2013, 122, 3375-3375.	0.6	0
133	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2926-2926.	0.6	0
134	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. Blood, 2015, 126, 5264-5264.	0.6	0
135	Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score. Blood, 2018, 132, 1833-1833.	0.6	0
136	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). Blood, 2018, 132, 3116-3116.	0.6	0
137	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. Blood, 2018, 132, 1857-1857.	0.6	0
138	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. Blood, 2018, 132, 4399-4399.	0.6	0
139	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. Blood, 2018, 132, 4394-4394.	0.6	0
140	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). Blood, 2018, 132, 5538-5538.	0.6	0
141	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. Blood, 2019, 134, 3022-3022.	0.6	0
142	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). Blood, 2019, 134, 852-852.	0.6	0
143	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. Blood, 2019, 134, 3037-3037.	0.6	0
144	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. Blood, 2020, 136, 35-36.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
146	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 12-13.	0.6	0